The new facility raises production capacity by an additional 19,100 m2 and creates 200 new full-time jobs.
On Oct. 7, 2019, Janssen Sciences Ireland UC, part of the Johnson & Johnson family of companies, officially opened its new manufacturing building in Ringaskiddy, Co. Cork, Ireland, in a ceremony attended by Simon Coveney, An Tánaiste and minister for Foreign Affairs & Trade, Kathy Wengel, executive vice-president and chief Global Supply Chain officer, Johnson & Johnson, and Martin Shanahan, CEO, IDA Ireland, according to an IDA Ireland press release.
The expansion of the biomanufacturing site increases the company’s production capacity by an additional 19,100 m2 and creates 200 new full-time jobs. Approximately 450 people were employed on-site during the two-year construction project.
“I’m delighted to attend the official opening of Janssen’s new manufacturing building, which marks the company’s ongoing commitment to Ireland and patients around the world. The life sciences industry makes a hugely significant contribution to the national economy in terms of jobs and exports. In 2018 alone, 33% of Ireland’s total exports were pharmaceutical and medical products, with Johnson & Johnson featuring as one of our single largest exporters. Finally, I would like to extend my congratulations to the team here in completing this exciting expansion and I wish them continued success in the future,” said Coveney in the press release.
“Our manufacturing facilities in Cork are at the cutting-edge of delivering healthcare solutions, which is an important part of our Credo commitment to provide the highest quality products to patients. Our Ringaskiddy facility is an important part of our global manufacturing network and expanding our capabilities here will allow us to pursue innovative solutions that advance how medicines are manufactured so that we can be at the forefront of treating, preventing, intercepting, and curing some of the world’s most devastating and complex diseases,” said Wengel in the release.
“Johnson & Johnson is one of the largest life sciences and R&D investors in Ireland and is part of a thriving Biopharma sector in Cork. With a significant investment in expanding Janssen’s manufacturing capacity here in Ringaskiddy, the positive economic spin-off for the South-West region is considerable. On behalf of IDA Ireland, I would like to congratulate the Janssen team on successfully delivering a new, state-of-the-art manufacturing building in the heart of Cork’s life sciences hub,” added Shanahan in the press release.
Source: IDA Ireland
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.